INS and Insulin resistance: Although no significant differences were observed in body weights or HbA1c levels between the groups, plasma glucose, plasma insulin, and HOMA-IR were significantly decreased from baseline in the empagliflozin group compared to the sitagliptin group values, indicating that empagliflozin can improve insulin resistance, an independent risk factor for CVD [53, 54].